ChemPartner’s antibody discovery team has over 200 scientists, 30 of which are PhDs or MDs. Our scientists are capable of discovering novel high-affinity monoclonal antibodies by hybridoma technology, B cell cloning technology and phage display technology. We can also develop humanized mouse/rat/rabbit monoclonal antibodies, fully human monoclonal antibodies, affinity matured monoclonal antibodies, single domain nanobody, bi/multi-specific antibodies, and antibody-drug conjugates.
